Evidence map›Paper›PMID 21306365›Full record

ArticleHealth services research2011

Cost implications of improving blood pressure management among U.S. adults.

Teryl K Nuckols, Julia E Aledort, John Adams, Julie Lai, Myong-Hyun Go, Joan Keesey, Elizabeth McGlynn

Abstract read
In one paragraph

Article in Health services research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves.Medical decision making : an international journal of the Society for Medical Decision Making · 2017
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Teryl K NuckolsRAND Corporation, 1776 Main Street, Santa Monica, CA 90407, USA. teryl@rand.org
Julia E Aledort
John Adams
Julie Lai
Myong-Hyun Go
Joan Keesey
Elizabeth McGlynn

Funding

The Value of Hospital-Related Patient-Safety Interventions to Key StakeholdersK08HS017954 · AHRQ · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NUCKOLS, TERYL · 2009 to 2012
$553k
AHRQ HHS HS17954AHRQ HHS K08 HS017954
6 · The paper itself

Abstract

objectiveTo examine the cost-effectiveness of improving blood pressure management from the payer perspective. DATA SOURCE/STUDY

settingMedical record data for 4,500 U.S. adults with hypertension from the Community Quality Index (CQI) study (1996-2002), pharmaceutical claims from four Massachusetts health plans (2004-2006), Medicare fee schedule (2009), and published literature. STUDY

designA probability tree depicted blood pressure management over 2 years. DATA COLLECTION/EXTRACTION

methodsWe determined how frequently CQI study subjects received recommended care processes and attained accepted treatment goals, estimated utilization of visits and medications associated with recommended care, assigned costs based on utilization, and then modeled how hospitalization rates, costs, and goal attainment would change if all recommended care was provided. PRINCIPAL

findingsRelative to current care, improved care would cost payers U.S.$170 more per hypertensive person annually (2009 dollars). The incremental cost per person newly attaining treatment goals over 2 years would be U.S.$1,696 overall, U.S.$801 for moderate hypertension, and U.S.$850 for severe hypertension. Among people with severe hypertension, blood pressure would decline substantially but seldom reach goal; the incremental cost per person attaining a relaxed goal (≤ stage 1) would be U.S.$185.

conclusionsUnder the Health Care Effectiveness Data and Information Set program, which monitors the attainment of blood pressure treatment goals, payers will find it slightly more cost-effective to improve care for moderate than severe hypertension. Having a secondary, relaxed goal would substantially increase payers' incentive to improve care for severe hypertension.

Indexed as

Blood PressureAntihypertensive AgentsCost-Benefit AnalysisCounselingDrug UtilizationHealth ServicesHumansHypertensionLife StyleModels, EconomicOffice VisitsQuality of Health CareSeverity of Illness IndexAntihypertensive Agents

Identifiers

PMID21306365
PMCPMC3165181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.